Resource Centers
Spotlight
Business
News
Conferences
Partners
CME/CE
Subscribe
- Drug Coverage
- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Safety & Recalls
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
Top 5 HIV Articles in 2023
This year's top HIV articles include one sharing data from a group of researchers from University of Pittsburgh who looked to see if T cell activation is sufficient to drive SIV disease progression.
- T Cell Activation Seen as Insufficient to Drive HIV Infection
Chronic T cell immune activation and inflammation are key features of HIV-1 infection in humans and simian immunodeficiency virus (SIV) infection of rhesus macaques, and a group of researchers from University of Pittsburgh looked to see if T cell activation is sufficient to drive SIV disease progression.
Read here - Immune Checkpoint Inhibitors Study for People Living With HIV Shows Promising Results
Researchers and clinicians have been wary of treating people living with HIV with Keytruda, Opdivo and other immune checkpoint inhibitors because removing an inhibitory step in the immune response was seen as risky for people with compromised immune systems.
Read here - HIV Stays Controlled in These Individuals Even After They Stop Treatment. Understanding Why Could Provide Clues to a ‘Functional Cure'
A team of researchers studied 22 HIV 'post-treatment controllers' — people whose HIV infections are kept in check even after stopping antiretroviral therapy.
Read here - Advancing Options for Gene Editing for HIV-1
CRISPR gene-editing therapy is predicted to cost about $1 million dollars per person which is considerably more expensive than keeping a patient on ART for the rest of their life.
Read here - On Long-Term Treatment, Piggybacking on Hepatitis C Eradication and the ‘Biggest Buzz' in HIV: A Conversation with Angel I. Ribó, PA-C, MPAS
Ribó is the faculty advisor to new POCN Center for HIV Excellence that will provide information and resources to providers who may see relatively few patients with HIV.
Read here
Related Videos
Related Content
